In response to the external environment, and as we announced at our Investor Day in March 2013, updated in May this year, we have made a clear set of strategic choices.
UCB is committed to providing the opportunity to patients to make informed decisions about participating in clinical trials.
First and only concentrated mealtime insulin analog may help people with diabetes fit their treatment into their daily lives.Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), the first and only concentrated mealtime insulin analog in the U.S., is now available .
OncoMed Pharmaceuticals and Bayer HealthCare Expand Cancer Stem Cell Collaboration with Clinical Manufacturing Agreement
OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics targeting cancer stem cells, today announced it has expanded its collaboration with Bayer HealthCare. Bayer’s U.S. affiliate will manufacture clinical supplies of a second Wnt inhibitor in the alliance.
Merck & Co., Inc. said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.
Medicis Pharmaceutical Corporation and Anacor Pharmaceuticals, Inc. announced that the two companies have entered into a research and development agreement to discover and develop boron-based small molecule compounds directed against a target for the potential treatment of acne.
GlaxoSmithKline plc announces that it has sold its entire holding of 30,755,151 shares of common stock in Quest Diagnostics Inc. (“Quest”). The sale comprised a secondary public offering by GSK (the “Offering”) and an accompanying repurchase of shares by Quest (the “Repurchase”). GSK originally acquired the shareholding as partial consideration for the sale of its clinical laboratories business in 1999 and has since gradually reduced its stake in stages.
Merck known outside the United States and Canada as MSD and PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that they have entered into an alliance by which PAREXEL will provide strategic access to global clinical development services for designated biosimilar candidates to Merck BioVentures. Merck BioVentures, a division of Merck, is focused on the delivery of high quality biosimilars to the patients that need them.
Page 1 of 3